Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating Expenses    
Research and development expenses $ 1,627,480 $ 2,043,984
General and administrative expenses 2,478,055 1,184,730
Operating Loss (4,105,535) (3,228,714)
Other Income (Expense), net 83,462 1,583
Net Operating Loss Before Income Tax Benefit (4,022,073) (3,227,131)
Income Tax Benefit
Net Loss $ (4,022,073) $ (3,227,131)
Net Loss Per Common Share - Basic and Diluted $ (0.18) $ (0.20)
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted 22,770,789 15,831,118